NCT06865885 - LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

April 3, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

December 31, 2026

Conditions

Drug InteractionsPrimary PreventionCardiometabolic SyndromeLDL-Cholersterol Lowering

Interventions

DRUG

Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL

The intervention arm will receive subcutaneous injection of inclisiran 284mg at the baseline visit, 3 months and 9 month visit.

Trial Locations (1)

RECRUITING

UC San Diego Altman Clinical and Translational Research Institute, La Jolla